Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
2 recherche sur le mot-clé 'Opioid'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Brief Report: Maternal Opioid Prescription from Preconception Through Pregnancy and the Odds of Autism Spectrum Disorder and Autism Features in Children / E. RUBENSTEIN in Journal of Autism and Developmental Disorders, 49-1 (January 2019)
[article]
Titre : Brief Report: Maternal Opioid Prescription from Preconception Through Pregnancy and the Odds of Autism Spectrum Disorder and Autism Features in Children Type de document : Texte imprimé et/ou numérique Auteurs : E. RUBENSTEIN, Auteur ; J. C. YOUNG, Auteur ; Lisa A. CROEN, Auteur ; Carolyn G. DIGUISEPPI, Auteur ; N. F. DOWLING, Auteur ; L. C. LEE, Auteur ; Laura A. SCHIEVE, Auteur ; Lisa D. WIGGINS, Auteur ; J. DANIELS, Auteur Article en page(s) : p.376-382 Langues : Anglais (eng) Mots-clés : Asd Developmental disorder Opioid Pregnancy Risk factor Index. décimale : PER Périodiques Résumé : Opioid use during pregnancy is associated with suboptimal pregnancy outcomes. Little is known about child neurodevelopmental outcomes. We examined associations between maternal opioid prescriptions preconception to delivery (peri-pregnancy) and child's risk of ASD, developmental delay/disorder (DD) with no ASD features, or ASD/DD with autism features in the Study to Explore Early Development, a case-control study of neurodevelopment. Preconception opioid prescription was associated with 2.43 times the odds of ASD [95% confidence interval (CI) 0.99, 6.02] and 2.64 times the odds of ASD/DD with autism features (95% CI 1.10, 6.31) compared to mothers without prescriptions. Odds for ASD and ASD/DD were non-significantly elevated for first trimester prescriptions. Work exploring mechanisms and timing between peri-pregnancy opioid use and child neurodevelopment is needed. En ligne : http://dx.doi.org/10.1007/s10803-018-3721-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=377
in Journal of Autism and Developmental Disorders > 49-1 (January 2019) . - p.376-382[article] Brief Report: Maternal Opioid Prescription from Preconception Through Pregnancy and the Odds of Autism Spectrum Disorder and Autism Features in Children [Texte imprimé et/ou numérique] / E. RUBENSTEIN, Auteur ; J. C. YOUNG, Auteur ; Lisa A. CROEN, Auteur ; Carolyn G. DIGUISEPPI, Auteur ; N. F. DOWLING, Auteur ; L. C. LEE, Auteur ; Laura A. SCHIEVE, Auteur ; Lisa D. WIGGINS, Auteur ; J. DANIELS, Auteur . - p.376-382.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 49-1 (January 2019) . - p.376-382
Mots-clés : Asd Developmental disorder Opioid Pregnancy Risk factor Index. décimale : PER Périodiques Résumé : Opioid use during pregnancy is associated with suboptimal pregnancy outcomes. Little is known about child neurodevelopmental outcomes. We examined associations between maternal opioid prescriptions preconception to delivery (peri-pregnancy) and child's risk of ASD, developmental delay/disorder (DD) with no ASD features, or ASD/DD with autism features in the Study to Explore Early Development, a case-control study of neurodevelopment. Preconception opioid prescription was associated with 2.43 times the odds of ASD [95% confidence interval (CI) 0.99, 6.02] and 2.64 times the odds of ASD/DD with autism features (95% CI 1.10, 6.31) compared to mothers without prescriptions. Odds for ASD and ASD/DD were non-significantly elevated for first trimester prescriptions. Work exploring mechanisms and timing between peri-pregnancy opioid use and child neurodevelopment is needed. En ligne : http://dx.doi.org/10.1007/s10803-018-3721-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=377 Oxytocin in the Developing Brain: Relevance as Disease-Modifying Treatment in Autism Spectrum Disorders / Bice CHINI
in Neuronal and Synaptic Dysfunction in Autism Spectrum Disorder and Intellectual Disability / Carlo SALA
Titre : Oxytocin in the Developing Brain: Relevance as Disease-Modifying Treatment in Autism Spectrum Disorders Type de document : Texte imprimé et/ou numérique Auteurs : Bice CHINI, Auteur ; Marianna LEONZINO, Auteur ; Valentina GIGLIUCCI, Auteur Année de publication : 2016 Importance : p.253-266 Langues : Anglais (eng) Mots-clés : Autism Monoamines Neurodevelopment Opioid Oxytocin Oxytocin receptor Perinatal treatment Social behavior Index. décimale : SCI-D SCI-D - Neurosciences Résumé : Among the several neurobiological systems implicated in shaping social behavior, oxytocin (OXT) has been firmly established as a master regulator of the social brain. This has led OXT to be proposed as a drug to ameliorate social deficits in a number of neurodevelopmental and neuropsychiatric conditions including autism spectrum disorders (ASDs). OXT administration has indeed been shown to improve social symptoms in adult ASD patients; even more interestingly, OXT has been shown to regulate key neurodevelopmental events, which suggests that the peptide can modify the onset and progression of ASD symptoms in childhood. We will review here the anatomical and neurochemical basis of these actions, with a special emphasis on the interactions of OXT with other key neurotransmitter systems involved in the regulation of social behavior at the early postnatal developmental stages. En ligne : http://dx.doi.org/10.1016/B978-0-12-800109-7.00016-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=301 Oxytocin in the Developing Brain: Relevance as Disease-Modifying Treatment in Autism Spectrum Disorders [Texte imprimé et/ou numérique] / Bice CHINI, Auteur ; Marianna LEONZINO, Auteur ; Valentina GIGLIUCCI, Auteur . - 2016 . - p.253-266.
in Neuronal and Synaptic Dysfunction in Autism Spectrum Disorder and Intellectual Disability / Carlo SALA
Langues : Anglais (eng)
Mots-clés : Autism Monoamines Neurodevelopment Opioid Oxytocin Oxytocin receptor Perinatal treatment Social behavior Index. décimale : SCI-D SCI-D - Neurosciences Résumé : Among the several neurobiological systems implicated in shaping social behavior, oxytocin (OXT) has been firmly established as a master regulator of the social brain. This has led OXT to be proposed as a drug to ameliorate social deficits in a number of neurodevelopmental and neuropsychiatric conditions including autism spectrum disorders (ASDs). OXT administration has indeed been shown to improve social symptoms in adult ASD patients; even more interestingly, OXT has been shown to regulate key neurodevelopmental events, which suggests that the peptide can modify the onset and progression of ASD symptoms in childhood. We will review here the anatomical and neurochemical basis of these actions, with a special emphasis on the interactions of OXT with other key neurotransmitter systems involved in the regulation of social behavior at the early postnatal developmental stages. En ligne : http://dx.doi.org/10.1016/B978-0-12-800109-7.00016-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=301 Exemplaires
Code-barres Cote Support Localisation Section Disponibilité aucun exemplaire